EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction

João Pedro Ferreira, Milton Packer, Javed Butler, Francisco Vasques-Nóvoa, Pedro Marques, Stuart Pocock, Gerasimos Filippatos, Faiez Zannad, Stefan D Anker

JACC: Heart Failure · 2026-02 · 14 (2) · 102889

DOI: 10.1016/j.jchf.2025.102889 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2026-02. Verfasst von João Pedro Ferreira und 8 weiteren Autor:innen. Beteiligte Einrichtung: RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal; Université de Lorraine, Inserm, Centre …. Hauptthemen laut MEDLINE: Heart Failure, Glucosides, Benzhydryl Compounds, Stroke Volume. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Magnesium plays a central role in maintaining cellular homeostasis. Limited data exist on the clinical implications of magnesium derangements and the influence of sodium-glucose cotransporter 2 inhibitors on magnesium levels in heart failure with mildly reduced or preserved ejection fraction. OBJECTIVES: Using the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) population, the authors aimed to study the association of serum magnesium with outcomes, assess the impact of empagliflozin on serum magnesium levels, and explore the influence of serum magnesium on the effect of empagliflozin on the study outcomes. METHODS: Patients with heart failure with mildly reduced or preserved ejection fraction were randomized to receive placebo or empagliflozin 10 mg daily. Laboratory results were available at baseline; week 4; weeks 12, 32, and 52; and every 24 weeks thereafter. The median follow-up time was 26.2 months. The primary outcome was a composite of cardiovascular death or heart failure hospitalization. RESULTS: A total of 5,988 patients were included. The mean serum magnesium levels at baseline were 0.82 ± 0.11 mmol/L. The corresponding magnesium quintiles were as follows: Q1 = 0.67 ± 0.07 mmol/L (n = 1,291), Q2 = 0.78 ± 0.02 (n = 1,189), Q3 = 0.83 ± 0.01 (n = 1,378), Q4 = 0.88 ± 0.01 (n = 1,078), and Q5 = 0.96 ± 0.05 (n = 1,052). Patients with higher magnesium levels were older, had lower estimated glomerular filtration rate, and higher prevalence of atrial fibrillation. Conversely, patients with lower serum magnesium had diabetes and used thiazide-type diuretic agents more frequently. Placebo-treated patients experienced a higher risk of primary outcome events with higher magnesium levels (Q5). Empagliflozin (vs placebo) was associated with a more pronounced reduction of primary outcome events at higher baseline magnesium levels: Q1, HR: 1.05 [95% CI: 0.77-1.39]; Q2, HR: 0.85 [95% CI: 0.63-1.14]; Q3, HR: 0.88 [95% CI: 0.66-1.17]; Q4, HR: 0.62 [95% CI: 0.45-0.86]; Q5, HR: 0.60 [95% CI: 0.45-0.79]; interaction P-trend = 0.030. At week 4, empagliflozin had increased magnesium levels by 0.05 mmol/L, reaching a steady state thereafter. CONCLUSIONS: In EMPEROR-Preserved, higher serum magnesium levels were associated with a higher risk of primary outcome events among patients treated with placebo but not among patients treated with empagliflozin who experienced pronounced benefit. (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction [EMPEROR-Preserved]; NCT03057951).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureGlucosidesBenzhydryl CompoundsStroke VolumeSodium-Glucose Transporter 2 InhibitorsMagnesiumHumansMaleFemaleAgedMiddle AgedDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

empagliflozinmagnesiumtreatment effect

Substanzen

empagliflozinGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsMagnesium

Autor:innen und Institutionen

  • RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal; Université de Lorraine, Inserm, Centre d'Investigations Cliniques, - Plurithématique 14-33, and Inserm U1116,…
  • Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA; Imperial College, London, United Kingdom.
  • Baylor Scott and White Research Institute, Dallas, Texas, USA; University of Mississippi, Jackson, Mississippi, USA.
  • RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.

Zitieren

APA

Ferreira, J. P., Packer, M., Butler, J., Vasques-Nóvoa, F., Marques, P., Pocock, S., Filippatos, G., Zannad, F., & Anker, S. D. (2026). Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 14(2), 102889. https://doi.org/10.1016/j.jchf.2025.102889

Vancouver

Ferreira JP, Packer M, Butler J, Vasques-Nóvoa F, Marques P, Pocock S, et al. Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure. 2026;14(2):102889. doi:10.1016/j.jchf.2025.102889

BibTeX
@article{Ferreira2026,
  author = {Ferreira, João Pedro and Packer, Milton and Butler, Javed and Vasques-Nóvoa, Francisco and Marques, Pedro and Pocock, Stuart and Filippatos, Gerasimos and Zannad, Faiez and Anker, Stefan D},
  title = {Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction},
  journal = {JACC: Heart Failure},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {102889},
  doi = {10.1016/j.jchf.2025.102889}
}
Kostenlos starten →